Quality control of diphtheria tetanus acellular pertussis combined (DTaP) vaccines in Japan

Japanese Journal of Infectious Diseases

Volumn 54, Issue 5, 2001, Pages 167-180

  Horiuchi, Yoshinobu ^a   Takahashi, Motohide ^a   Konda, Toshifumi ^a   Ochiai, Masaki ^a   Yamamoto, Akihiko ^a   Kataoka, Michiyo ^a   Toyoizumi, Hiromi ^a   Arakawa, Yoshichika ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; OUTER MEMBRANE PROTEIN; PERTUSSIS VACCINE; PLACEBO; TETANUS TOXOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG POTENCY; DRUG QUALITY; DRUG SAFETY; DRUG SYNTHESIS; DRUG USE; FEASIBILITY STUDY; IMMUNIZATION; JAPAN; LABORATORY TEST; MOUSE; NONHUMAN; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW; STANDARDIZATION; TOXICITY TESTING; VACCINATION; WORLD HEALTH ORGANIZATION;

ANIMALS; CHO CELLS; CRICETINAE; DIPHTHERIA; DIPHTHERIA TOXIN; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HUMANS; JAPAN; MICE; QUALITY CONTROL; TETANUS; TETANUS TOXIN; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 0035698333     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Vaccination against whooping cough: Correlation between protection in children and results of laboratory tests
2. Standardization of acellular pertussis vaccines
3. WHO guidelines for the production and control of the acellular pertussis component of monovalent or combined vaccines
4. Japan's experience in pertussis epidemiology and vaccination in the past thirty years
5. Experiences with acellular pertussis vaccine in Japan and epidemiology of pertussis
6. Studies on protective antigen of Bordetella pertussis: Isolation of protective antigen by sucrose density gradient centrifugation and some properties of the antigen
7. Isolation of protective antigen from Bordetella pertussis
8. The haemagglutinin of Haemophilus pertussis. I. Haemagglutinin as a protective antigen in experimental murine pertussis
9. On the relationship between histamine sensitizing factor and mouse protective antigen
10. The soluble protective antigen and the histamine-sensitizing factor of Bordetella pertussis
11. Leukocytosis-promoting factor of Bordetella pertussis III. Its identity with protective antigen
12. Hemagglutinating substance of Bordetella pertussis
13. The purification and characterization of an acellular pertussis vaccine
14. Overview of currently available Japanese acellular pertussis vaccines and future problems
15. Lymphocytosis-promoting factor produced by Bordetella pertussis. Partial purification and characterization
16. Characterization of the body weight decreasing toxicities in mice by the lymphocytosis-promoting factor and the heat-labile toxin of B. pertussis and endotoxin
17. Factors influencing the assay of the histamine-sensitizing factor of Haemophilus pertussis
18. A new biological assay method for histamine-sensitizing factor using survival time as a response
19. Toxicity and toxicity testing of pertussis vaccine
20. Determination of the epinephrine-refractory hypoglycaemic activity of whole cell pertussis vaccine in mice
21. A sensitive assay method for the histamine-sensitizing factor using change in rectal temperature of mice after histamine challenge as a response
22. Development of pertussis vaccine production and control in the National Institute of Public Health in the Netherlands during the years 1950-1962
23. Determination of the histamine sensitizing unitage of pertussis vaccine
24. Development of a pertussis component vaccine in Japan
25. What's in a name? The meaning of the term "potency", as applied to immunologicals for human use, and its implications for alternatives and validation
26. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis
27. Protection against intranasal infection of mice with Bordetella pertussis
28. Quantitative estimation of diphtheria and tetanus toxoids. 5. Comparative assays in mice and in guinea-pigs of two diphtheria toxoid preparations
29. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series
30. Overview of recent clinical trials of acellular pertussis vaccines
31. Acellular pertussis vaccines: The rationale for an efficacy trial in Germany
32. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure
33. Efficacy of acellular pertussis vaccine in early childhood after household exposue
34. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis
35. Preliminary report on household contact studies of the prevention of pertussis in Japanese children by Takeda diphtheria and tetanus toxoids and acellular pertussis vaccine combined
36. Clinical efficacy of the Japanese acellular pertussis vaccine after intrafamiliar exposure to pertussis patients
37. Protection against pertussis by Takeda's acellular pertussis vaccine: Household contact studies in Kawasaki City, Japan
38. Optimization of immunization schedule to standardize antibody response in mice to pertussis vaccines
39. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers
40. The Swedish efficacy trial of acellular pertussis vaccines-update and time for reflection
41. Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines
42. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle against Bordetella parapertussis infection
43. Clinical studies on efficacy and safety of acellular pertussis vaccine
44. Acellular and whole cell pertussis vaccines protect against the lethal effects of intracerebral challenge by two different T-cell dependent humoral routes
45. Cell-mediated immunity to Bordetella pertussis: Role of Th1 cells in bacterial clearance in a murine respiratory infection model
46. Passive protection of mice by two antigenic preparations of Bordetella pertussis comprising mainly pertussis toxin or filamentous hemagglutinin as measured by two intracerebral mouse protection tests
47. Antibody response to pertussis toxin and filamentous haemagglutinin in NIH mice immunized with the international standard for pertussis vaccine
48. Structure and biological properties of solubilized envelope proteins of Bordetella pertussis
49. Synergistic effect of Bordetella pertussis lymphocytosis-promoting factor on protective activities of isolated Bordetella antigen in mice
50. Protective antigen of Haemophilus pertussis
51. Developments in pertussis vaccines leading to reduction and replacement of in vivo testing
52. Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events
53. A placebo-controlled trial of a pertussis-toxoid vaccine
54. Primum non nocere: A pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine
55. Mechanism of pertussis toxin B oligomer-mediated protection against Bordetella pertussis respiratory infection
56. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity
57. Effects of recombinant murine (rm) interleukin-12 and rm interferon-gamma in mice infected with Bordetella pertussis
58. Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis
59. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA
60. Protection of mice from Bordetella pertussis respiratory infection using microencapsulated pertussis fimbriae
61. Bordetella pertussis filamentous hemagglutinin: Evaluation as a protective antigen and colonization factor in a mouse respiratory infection model
62. Construction and analysis of Bordetella pertussis mutants defective in the production of fimbriae
63. Role of antibodies against Bordetella pertussis virulence factors in adherence of Bordetella pertussis and Bordetella parapertussis to human bronchial epithelial cells
64. The comparison between field trials and mouse protection tests against intranasal and intracerebral challenges with Bordetella pertussis
65. Potency tests of diphtheria, tetanus and combined vaccines suggestion for a simplified potency assay
66. Standardization and control of toxoid components in the combined vaccine (DPT)
67. Studies on the effectiveness and untoward reaction of combined diphtheria and tetanus toxoid
68. Bio-assay of four tetanus toxoids (aluminium precipitated) in mice, guinea-pigs and humans
69. The potency testing of diphtheria and tetanus toxoids as determined by the induction of antibody in mice
70. An investigation of a mouse model to estimate the potency of the diphtheria component in vaccines
71. Quantitative estimation of diphtheria and tetanus toxoids. 3. Comparative assays in mice and in guinea-pigs of two tetanus toxoid preparations
72. Report of an informal meeting about alternative methods for the potency control of the diphtheria and tetanus components in vaccines
73. Standardization of tetanus toxoid combined with pertussis vaccine
74. Studies on the combined vaccine. I. On the antigenicity of diphteria toxoid
75. Studies on the combined vaccine (pertussis-diphtheria-tetanus). II. On the antigenicity of tetanus toxoid
76. Quantitative estimation of diphtheria and tetanus toxoids. 5. Comparative assays in mice and in guinea-pigs of two diphtheria toxoid preparations
77. Quantitative estimation of diphtheria and tetanus toxoids. 6. Use of different antibody titration methods for evaluation of immunogenicity in animals during potency assay of diphtheria toxoid
78. Study on adjuvants for human prophylactics. I. Comparison of efficiencies of different adjuvants at various stages of immunization with tetanus and diphtheria toxoids
79. Are potency tests for tetanus vaccines really necessary?
80. A comparison of the antigenic characteristics of mixed antigens in the child and the guinea-pigs
81. Opportunities to reduce the use of animals in the potency and rtoxicity testing of toxoid vaccines
82. Combination of DTP and Haemopgilus influenzae type b conjugate vaccines can affect laboratory evaluation of potency and immunogenicity
83. Interaction of Haemopgilus influenzae type b conjugate vaccines with diphtheria-tetanus-pertussis vaccine in control tests
84. Difference in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants
85. Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines
86. Titration of tetanus antitoxin by passive hemagglutination. I. Titration of guinea-pig antitoxins at various periods of immunization
87. Measurement of human tetanus antitoxin using as enzyme-linked immunosorbent assay
88. The toxin binding inhibition test as a reliable in vitro alternative to the toxin neutralization test in mice for the estimation of tetanus antitoxin in human sera
89. Development and usefulness of the gelatin-particle-agglutination test for titration of antibodies against diphtheria, pertussis and tetanus toxins
90. Titration of antibodies to tetanus toxoid by agglutination of purified tetanus toxoid sensitized latex particles
91. Micro cell culture method for determination of diphtheria toxin and antitoxin titers using Vero cells. II. Comparison with the rabbit skin method and practical application for sero-epidemiological studies
92. Successful control of epidemic diphtheria in the states of the Former Union of Soviet Socialist Republics: Lessons learned
93. Analysis of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain
94. Developments in pertussis immunisation in Japan
95. A new chromogenic endotoxin-specific assay using recombined limulus coagulation enzymes and its clinical applications
96. Limulus test for detecting bacterial endotoxins
97. Limulus test for detecting bacterial endotoxins
98. Development of an endotoxin-specific Limulus amebocyte lysate test blocking beta-glucan-mediated pathway by carboxymethylated curdlan and its application
99. An automated analysis system of Limulus amebocyte lysate (LAL)-endotoxin reaction kinetics using turbidimetric kinetic assay
100. Lymphocytosis-promoting factor produced by Bordetella pertussis
101. Selective breeding to establish a standard mouse for pertussis vaccine bioassay. II. Bioresponses of mice susceptible and resistant to sensitization by pertussis vaccine HSF
102. A curious histamine-sensitizing activity shown by the newly-developed Japanese acellular pertussis vaccine
103. Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin
104. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques
105. Increased levels of active pertussis toxin may aid a pertussis vaccine to pass the mouse body weight gain test
106. The effects of purified pertussis components and lipopolysaccharide on the result of the mouse weight gain test
107. The effect of purified components of Bordetella pertussis in the weight gain test for the toxicity testing of pertussis vaccines
108. Interfering effect of diphtheria-tetanus-acellular pertussis (DTaP) vaccines to the bacterial endotoxin test